

Display Settings: Abstract

Send to:



J Bioenerg Biomembr. 2012 Feb;44(1):141-53. doi: 10.1007/s10863-012-9418-3. Epub 2012 Feb 17.

Butyrate activates the monocarboxylate transporter MCT4 expression in breast cancer cells and enhances the antitumor activity of 3-bromopyruvate.

Queirós O, Preto A, Pacheco A, Pinheiro C, Azevedo-Silva J, Moreira R, Pedro M, Ko YH, Pedersen PL, Baltazar F, Casal M.

Centro de Investigação em Ciências da Saúde, Instituto Superior de Ciências da Saúde-Norte / CESPU, Rua Central de Gandra, 1317, 4585-116 Gandra, PRD, Portugal.

Abstract

Most malignant tumors exhibit the Warburg effect, which consists in increased glycolysis rates with production of lactate, even in the presence of oxygen. Monocarboxylate transporters (MCTs), maintain these glycolytic rates, by mediating the influx and/or efflux of lactate and are overexpressed in several cancer cell types. The lactate and pyruvate analogue 3-bromopyruvate (3-BP) is an inhibitor of the energy metabolism, which has been proposed as a specific antitumor agent. In the present study, we aimed at determining the effect of 3-BP in breast cancer cells and evaluated the putative role of MCTs on this effect. Our results showed that the three breast cancer cell lines used presented different sensitivities to 3-BP: ZR-75-1 ER (+)>MCF-7 ER (+)>SK-BR-3 ER (-). We also demonstrated that 3-BP reduced lactate production, induced cell morphological alterations and increased apoptosis. The effect of 3-BP appears to be cytotoxic rather than cytostatic, as a continued decrease in cell viability was observed after removal of 3-BP. We showed that pre-incubation with butyrate enhanced significantly 3-BP cytotoxicity, especially in the most resistant breast cancer cell line, SK-BR-3. We observed that butyrate treatment induced localization of MCT1 in the plasma membrane as well as overexpression of MCT4 and its chaperone CD147. Our results thus indicate that butyrate pre-treatment potentiates the effect of 3-BP, most probably by increasing the rates of 3-BP transport through MCT1/4. This study supports the potential use of butyrate as adjuvant of 3-BP in the treatment of breast cancer resistant cells, namely ER (-).

PMID: 22350013 [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances, Grant Support

LinkOut - more resources

Save items

Add to Favorites

Related citations in PubMed

CD147 subunit of lactate/H+ symporters MCT1 ; [Proc Natl Acad Sci U S A. 2011]

Evidence for a stromal-epithelial "lactate shuttle" in human tumor [Cell Cycle. 2011]

Monocarboxylate transporter 4 regulates maturation and traffic [Cancer Res. 2007]

Review Role of monocarboxylate transporters [J Bioenerg Biomembr. 2012]

Review Nutrient transporters in cancer: relevance to Warl [Pharmacol Ther. 2009]

See reviews...

See all...

Related information

Related Citations

Compound (MeSH Keyword)

OMIM (calculated)

Substance (MeSH Keyword)

Recent activity

Turn Off Clear

Butyrate activates the monocarboxylate transporter PubMed

See more...

You are here: NCBI > Literature > PubMed

Write to the Help Desk

GETTING STARTED

NCBI Education
NCBI Help Manual
NCBI Handbook
Training & Tutorials

RESOURCES

Chemicals & Bioassays
Data & Software
DNA & RNA
Domains & Structures
Genes & Expression
Genetics & Medicine
Genomes & Maps
Homology
Literature
Proteins
Sequence Analysis
Taxonomy
Training & Tutorials
Variation

POPULAR

PubMed
Nucleotide
BLAST
PubMed Central
Gene
Bookshelf
Protein
OMIM
Genome
SNP
Structure

FEATURED

Genetic Testing Registry
PubMed Health
GenBank
Reference Sequences
Map Viewer
Human Genome
Mouse Genome
Influenza Virus
Primer-BLAST
Sequence Read Archive

NCBI INFORMATION

About NCBI
Research at NCBI
NCBI Newsletter
NCBI FTP Site
NCBI on Facebook
NCBI on Twitter
NCBI on YouTube

Copyright | Disclaimer | Privacy | Browsers | Accessibility | Contact

National Center for Biotechnology Information, U.S. National Library of Medicine
8600 Rockville Pike, Bethesda MD, 20894 USA

